ERBB2 and breast cancer: Although a certain percentage of patients have not achieved a complete pathological response and survival outcome, this FUSCC breast cancer dataset still provides powerful evidences to uncover the changing roles of PIK3CA mutations in treatment‐naïve or early‐stage patients and advanced‐stage HER2+ patients.